Fernando Arias-Mendoza1, Geoffrey Payne2, Kristen Zakian3, Marion Stubbs4, Hamed Mojahed1, Amita Shukla-Dave3, Nicholas R. Maisey2, David Cunningham2, Harish Poptani5, Mitchell R. Smith6, Owen A. O'Connor7, Jazmine Zain7, Steven J. Shuster8, Andrew D. Zelenetz9, George A. Follows10, John Raemaekers11, Marius MacKenzie11, Martin O. Leach2, Jason A. Koutcher3, John R. Griffiths4, Arend Heerschap12, Jerry D. Glickson5, Truman R. Brown1
1Radiology, Columbia University, New York, NY, USA; 2Radiology, Royal Marsden Hospital, London, UK; 3Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 4Radiology, Cambridge University, Cambridge, UK; 5Radiology, University of Pennsylvania, Philadelphia, PA, USA; 6Clinical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 7Clinical Oncology, Columbia University, New York, NY, USA; 8Clinical Oncology, University of Pennsylvania, Philadelphia, PA, USA; 9Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 10Clinical Oncology, Addenbroke's Hospital, Cambridge, UK; 11Clinical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 12Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
In this work, we studied less frequent histological subtypes of non Hodgkin's lymphomas (mainly follicular and mantle cell lymphomas) to test the utility of the [Etn P + Cho P]/NTP ratio in predicting treatment failure and drug-free survival in these patients.Our results show that even though there is more overlap between the complete and not complete response groups in NHL types studied here, the prediction of treatment response and disease-free survival by [Etn P + Cho P]/NTP determined by 31P-MRS is still applicable to these more infrequent forms of NHL.